Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Chameleon Biosciences Presents Poster on AAV Gene Therapy Redosing Success at ESGCT
Details : The Chameleon poster presentation describes how EVADER resulted in increased potency and redosing potential for enhanced AAV transduction in mice and in non-human primates.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 10, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable